NEOGNeogen Corporation
Is the price fair?
A demanding price: priced for +21% a year vs +2% a year delivered and at the top of its own P/E range.
Priced for ~21% a year FCF growth. The price already bakes in strong, sustained growth.
Expensive vs its own history: P/E 242.4 vs a 61.7 median over 26 quarters (+293% vs median).
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What NEOG's price assumes
Neogen Corporation did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 2.38× revenue.
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 1.5%
Free cash flow yield · Medical Devices median 4.5%
- Growth the price implies
- +21%
Growth the price implies · The price pays for +21% free cash flow growth a year for a decade; revenue has grown +1.9% a year over the last three.
- Price / book
- 0.99
Price / book · today's price, trailing year to May 31, 2026
Details›
- Price / booktoday's price, trailing year to May 31, 2026
- 0.99
- EV / EBIToperating margin −2.5%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, trailing year to May 31, 2026
- 4.00
- Free cash flow, trailing twelve months
- $32M
- Market capitalisation
- $2.07B
- 3-year revenue growth
- +1.9%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.